Mechanisms of metabolic transition in hypertrophic cardiomyopathy

Conghao Tan1, Zhexuan Guo1, Junjie Zhou1

  • 1Department of Cardiovascular Medicine, Zhenjiang First People's Hospital, Zhenjiang, Jiangsu, China.

Frontiers in Physiology
|November 28, 2025
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) involves altered cardiac cell metabolism. Understanding this metabolic transition is key to developing new diagnostic and treatment strategies for this heart disease.

Area of Science:

  • Cardiology
  • Biochemistry
  • Molecular Biology

Background:

  • Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease with significant global health impact.
  • Current treatments improve prognosis but do not fully address the disease burden.
  • Metabolic transition in cardiac cells is increasingly recognized as a critical factor in HCM progression.

Purpose of the Study:

  • To elucidate the role of metabolic transition in the pathogenesis of Hypertrophic cardiomyopathy.
  • To identify potential therapeutic targets by understanding altered metabolic pathways in HCM.

Main Methods:

  • Review and synthesis of current research on metabolic alterations in HCM.
  • Analysis of changes in glucose, lipid, and amino acid metabolism in cardiomyocytes.
  • Correlation of metabolic shifts with clinical manifestations like fibrosis and diastolic dysfunction.

Main Results:

  • HCM hearts show increased reliance on glycolysis and impaired aerobic glucose oxidation.
  • Defects in fatty acid beta-oxidation lead to lipid accumulation (ceramides, sphingomyelins).
  • Altered amino acid metabolism, including elevated branched-chain amino acids, is linked to cardiac remodeling and insulin resistance.

Conclusions:

  • Metabolic transition, encompassing shifts in glucose, lipid, and amino acid pathways, is central to HCM pathogenesis.
  • Understanding these metabolic changes is crucial for developing novel diagnostic and therapeutic strategies for HCM.
  • Targeting metabolic pathways may improve patient outcomes and quality of life in Hypertrophic cardiomyopathy.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
374
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
685
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
314
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.7K
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
479
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
447